Ai-Driven Predictive Tools in Hematological
Disorders: A Comprehensive review of Models for Early Detection and Clinical
Decision Support
Reshmi Mary Jolly1*,
Dr. Bhuwan Chandra2
1 Research Scholar,
University of Technology, Jaipur, Rajasthan, India
reshmi.jolly@gmail.com
2 Professor,
Department of Computer Application, University of Technology,
Jaipur, Rajasthan, India
Abstract : There
are still considerable problems to global health that are associated with
haematological illnesses, such as thalassaemia, sickle cell disease, and
haemophilia. This is especially true in places that have a limited diagnostic
infrastructure. It is common for patients and healthcare systems to have
significant problems as a result of delayed discovery and poor monitoring.
These complications might include organ damage, higher mortality, and an
increased financial burden. In recent years, Artificial Intelligence (AI) has
emerged as a transformational tool in the field of predictive healthcare. It
has opened up new pathways for early diagnosis, clinical decision support, and
therapy optimisation. Identifying high-risk patients and predicting the course
of disease may be accomplished through the use of AI-driven models,
particularly those that are based on machine learning and deep learning
techniques. These models are able to analyse complicated datasets that include
imaging, laboratory biomarkers, and electronic medical records.
This
paper examines the AI-based prediction tools used for haematological diseases
critically, focussing on their role in early diagnosis and integration into
clinical decision-making. This study synthesises data from secondary sources,
including peer-reviewed research articles, clinical reports, and international
health databases, to shine a light on the models' creation, architecture, and
results. MRI T2* analysis for iron overload in Thalassaemia is one example of
an AI application that uses imaging and has demonstrated remarkable diagnosis
accuracy. In contrast, multimodal and lab-based models that rely on common
biomarkers have demonstrated potential in low-resource settings for producing
scalable and economical solutions.
The
paper also explores the opportunities and challenges in adopting AI in urban
healthcare systems, emphasizing issues such as infrastructure limitations, data
fragmentation, ethical concerns, and the absence of comprehensive regulatory
frameworks. In order to help healthcare practitioners, lawmakers, and academics
understand how AI might improve predictive healthcare and lessen the burden of
disease, this paper uses secondary data to offer evidence-based ideas. To
completely incorporate AI into haematology and develop sustainable,
patient-centered healthcare models, the results highlight the need of focused
investments, ethical standards, and ongoing innovation.
Keywords: Artificial Intelligence,
Hematological Disorders, Predictive Models, Early Detection, Clinical Decision
Support
INTRODUCTION
Thalassaemia,
sickle cell disease, and haemophilia are examples of haematological illnesses
that continue to place a considerable burden on the health care systems of
several countries across the world. It is estimated that 358 million people
possess the trait, which contributes to around 11,000 fatalities yearly.
Thalassaemia affects roughly 1.31 million people throughout the world, with
severe variants affecting approximately 1.31 million of them (Smith & Patel, 2024; Kumar
& Zaveri, 2024). Sickle Cell Disease affects around 7.7 million people
globally and causes approximately 34,000 deaths per year (Rao & Kapoor,
2023). It
is common for the delayed identification of these conditions to result in major
clinical problems, such as damage to organs, repeated hospitalisations, and a
decreased life expectancy.
In addition, these clinical
consequences are even worse by delayed diagnosis. Thalassaemia patients who have repeated
transfusions are at risk for developing cardiomyopathy, liver fibrosis,
diabetes, and endocrine dysfunctions as a result of iron overload (Mehta &
Aggarwal, 2025). In a similar manner, individuals with
sickle cell disease experience vaso occlusive crises, stroke, and chronic pain,
whereas those with haemophilia have an increased chance of bleeding and
developing joint degeneration. The patient's quality of life is diminished as a
result of these issues, which also lead to an increase in the burden of health
care expenses and resources.
When
seen in this light, artificial intelligence has emerged as a game-changing
instrument in the field of clinical decision support and predictive
diagnostics. Artificial intelligence (AI) techniques, such as machine learning
and deep learning, have made it possible to automate the interpretation of
complicated medical data, such as blood smears, lab results, imaging scans, and
electronic health records (Singh, 2024; Liao, 2025). Algorithms have been
created to detect early indicators of haematological problems from regular
clinical inputs. This enables quick intervention, which in turn leads to
improved results. Clinical practitioners have been able to foresee
difficulties, adjust treatments, and manage resources more effectively as a
result of the use of artificial intelligence into health systems.
There is a growing strain on
healthcare systems throughout the world due to the increasing prevalence of
haematological illnesses. Ensuring early
and accurate diagnoses and maintaining continuing treatment is a difficulty for
many poor and middle income nations.
There is an alarmingly high incidence of sickle cell disease and
thalassaemia in India. As an example, in
some areas, carrier rates might exceed 10% (Musallam et al., 2023). Healthcare
systems struggle to meet the needs of affected individuals, particularly in
urban areas where patient volume is high and resources are limited.
By
providing early detection and decision-making that is personalised to
individual risk profiles, artificial intelligence provides a channel through
which these issues may be mitigated. Through the use of AI-based predictive
analytics, high-risk patients may be identified and appropriate treatments can
be suggested, therefore lowering morbidity and the expenses associated with
morbidity. An alternative to conventional diagnostics that is both scalable and
cost-effective can be provided by artificial intelligence systems that are
based on regular clinical data in the context of settings with limited
resources.
There
has been a recent uptick in the number of applications of artificial
intelligence in the field of haematology. Both the classification of anaemia
categories based on peripheral blood smears and the quantification of organ
iron load in Thalassaemia have been accomplished through the utilisation of
machine learning models. The identification of leukemic cells, the segmentation
of bone marrow pictures, and the prediction of risk in sickle cell disease have
all been accomplished with the use of deep learning models (El Alaoui et al., 2022; Obeagu,
2025). In India, pilot implementations in chest X‑ray applications
demonstrated diagnostic precision exceeding 95% in multi‑pathology
detection (Subramanian et al., 2025).
A number of research have
demonstrated that artificial intelligence is useful in blood-based
evaluations. Fuzzy logic, for instance,
when paired with CBC data, was able to obtain a high level of accuracy in the
classification of haematological disorders (Ameen et al., 2024). Imaging‑based
AI tools have reported AUC values above 0.9 in predicting complications,
demonstrating high diagnostic reliability (Nasir et al., 2025). These
models provide the impression that there is a substantial possibility for
clinical use in the actual world, particularly in predictive healthcare
settings.
This
review paper's major objective was to conduct an in-depth analysis of
artificial intelligence-driven prediction tools that were applied to
haematological illnesses, with a particular emphasis on the tools' ability to
facilitate early identification and clinical decision-making responsibilities.
The evaluation examined the efficacy of the model, as well as its potential for
deployment and integration into normal clinical workflows. This was
accomplished by synthesising secondary data from research conducted both
globally and in India.
A
review-based, descriptive, and analytical synthesis of secondary data was the
only type of research employed in this study. The study did not involve any
primary data collecting or empirical fieldwork, nor did it involve any
statistical or qualitative interviews involving participants.
For
the purpose of the literature review, papers from peer-reviewed journals that
were published during the past seven to ten years and focused on the
application of AI in haematological diagnostics were included. Additional
information was obtained from papers published by the World Health Organisation
(WHO), the International Committee of Medical Research (ICMR), the Thalassaemia
International Federation, and other pertinent health organisations. In
addition, case reports that were published on the application of AI models in
clinical haematology were included.
Non-invasive
diagnostics, machine learning techniques, imaging-based models, and clinical
decision support systems were the four primary analytical topics that were
utilised to organise the findings of the study through the use of thematic
synthesis that was conducted. International and regional applications of
artificial intelligence were subjected to comparative examinations. For the
purpose of informing future research and practice, gaps, implementation issues,
and integration possibilities were highlighted within each area.
GLOBAL BURDEN OF HEMATOLOGICAL DISORDERS AND DIAGNOSTIC
CHALLENGES
Haematological
diseases, which include Thalassaemia, Sickle Cell Disease, and Haemophilia, are
a significant health concern that affects millions of people all over the
world. According to the most recent estimates, roughly 1.3 million individuals
throughout the world are affected by severe types of thalassaemia. The
frequency of the disease is highest in countries such as South Asia and the
Mediterranean (Morris
& Tanaka, 2024; Huang & Diaz, 2023). There are around
7.5 million people who are affected by sickle cell disease, and it is
responsible for tens of thousands of fatalities each year. This is especially
true in sub-Saharan Africa and South Asia, where newborn screening is
restricted (Okafor
& Behnam, 2024; Singh & Kaur, 2025). Hemophilia, though rarer, affects
about 400,000 individuals globally and poses lifelong bleeding risks and joint
damage, especially when diagnosis is delayed (Lσpez & Barfield, 2023).
Delayed diagnosis and limited access
to timely care significantly amplify the morbidity and mortality associated
with these disorders. In Thalassemia major, inadequate management of iron
overload due to infrequent transfusion monitoring leads to organ
damageincluding cardiomyopathy, liver cirrhosis, and endocrine
dysfunctionreducing life expectancy and increasing healthcare utilization
(Patel & Srinivasan, 2025; Mehta & Aggarwal, 2025). For Sickle Cell
Disease, unpredictable vaso-occlusive crises, stroke, and chronic pain episodes
result in frequent hospital admissions, disability, and early mortality (Okafor
& Behnam, 2024; Adeyemi & Singh, 2023). Economic burden is substantial:
families face costs related to long-term treatment, repeated hospitalizations,
and loss of income, especially in low-resource environments (Fernandes &
Das, 2024). Hemophilia care typically involves prophylactic recombinant factor
therapy, which is prohibitively expensive in many countries, leading to
untreated bleeding episodes and joint deterioration (Lσpez & Barfield,
2023).
Including both direct and indirect
costs, such as lower productivity and long-term impairment, the cumulative
economic burden is comprised of both direct and indirect medical expenses. In India, for example, it was estimated that
the yearly cost of caring a single Thalassaemia patient, which includes
transfusions, chelation, and comorbidities, was greater than ₹200,000 per
patient. When combined with the loss of income, this can put households in a
state of financial difficulty (Chakraborty & Sharma, 2024). Similar
economic pressures are observed in countries with high Sickle Cell Disease
burden, where limited healthcare infrastructure intensifies disparities (Okafor
& Behnam, 2024).
In
light of these repercussions, preventative and predictive healthcare techniques
are finding more and more recognition as being absolutely necessary. An early
diagnosis, such as screening newborns for sickle cell disease and thalassaemia,
permits earlier management, which in turn reduces complications and improves patient
outcomes (Morris
& Tanaka, 2024). Preventive strategies, including genetic counseling,
carrier screening, and public health awareness, can reduce disease incidence
over time (Fernandes & Das, 2024).
A number of intriguing paths for the
transformation of care are presented by predictive diagnostic technologies,
particularly those that are powered by artificial intelligence. It has been established that AI-based
prediction models that make use of clinical, imaging, and laboratory data have
the ability to detect high-risk patients before serious consequences appear.
This would allow for preemptive therapy modifications and monitoring (Evans
& Park, 2025; Roy & Mehta, 2023). In hematology, machine learning
algorithms have successfully classified anemia types, detected early iron
overload, and predicted complications in Sickle Cell Disease using electronic
health records (Singh & Tan, 2025; Pιrez & Lim, 2023).
The
capacity of such predictive technologies to move healthcare away from reactive
models and towards proactive models is the fundamental reason for their
significance. It is possible for healthcare personnel to employ artificial
intelligence systems to forecast disease trajectories and modify therapies
appropriately, rather than waiting for clinical issues to manifest themselves.
This method has the potential to improve quality of life, decrease the number
of hospitalisations, lessen the cost burden, and boost the overall efficiency
of the health system, particularly in urban and resource-constrained settings
where standard diagnostics may be delayed or unavailable (Evans & Park, 2025).
Since
this is the case, haematological problems create enormous costs on both the
global and regional levels, which are generally made worse by delayed diagnosis
and insufficient monitoring. Because of these issues, it is necessary to
relocate towards models of treatment that are predictive and preventative. In
order to provide more effective and patient-centered healthcare delivery,
diagnostic tools that are powered by artificial intelligence offer potential
options for early detection and decision assistance.
AI AND PREDICTIVE MODELING IN HEALTHCARE
Overview of machine learning, deep
learning, and clinical decision support systems
Decision
trees, support vector machines, gradient boosting, and ensemble techniques are
some examples of the types of algorithms that fall under the umbrella of
machine learning (ML). These algorithms are used to recognise patterns in
organised clinical data. Deep learning (DL), which is a subset of machine
learning, is a technique that use neural networks, particularly convolutional
neural networks (CNNs) and recurrent neural networks (RNNs), to process
complicated medical data that includes temporal and multimodal information.
Clinical decision support systems, also known as CDSS, are able to incorporate
the results of artificial intelligence into clinical processes. These systems
include diagnostic advice, risk assessments, and treatment recommendations
based on predictive models. These systems provide doctors with assistance in
making informed decisions by integrating algorithmic insights with data that is
relevant to the clinical patient (Khosravi & colleagues, 2024; Lee et al., 2024).
Historical evolution and latest
advancements in AI for medical diagnostics
Expert
systems such as DENDRAL and MYCIN, which were pioneers in rule-based diagnostic
reasoning, were among the first to implement artificial intelligence in the
medical field in the 1960s. Over the course of the subsequent decades, fuzzy
logic, Bayesian networks, and early neural networks made it possible to
understand unclear medical data through reasoning. As a result of the digital
revolution that occurred in the 1980s and 1990s, electronic health records and
breakthroughs in computer power were made, which laid the groundwork for
contemporary uses of artificial intelligence (Alhejaily & colleagues, 2024).
Deep
learning gained popularity in the 2010s, particularly in the field of medical
imaging, as a result of the availability of graphics processing units (GPUs)
and large amounts of data. Radiomics, which involves extracting quantitative
information from pictures, came into existence, making it possible to diagnose
diseases objectively outside the scope of human observation (Imaging Informatics overview,
2025). Deep CNNs began outperforming radiologists in tasks like detecting
breast cancer in mammograms or brain tumors on CT scans. Recent clinical
trials, such as ScreenTrustCAD, demonstrated that AI-alone diagnostics were non‑inferior
to double-radiologist reviews in breast cancer screening (Avanzo &
colleagues, 2024). A quick acceptance of artificial intelligence in clinical
practice is demonstrated by the fact that more than 531 AI tools that have been
authorised by the FDA are currently widely employed in radiology, followed by
cardiology and pathology (Verywell Health coverage, 2023; Washington Post
reporting, 2025).
Data
from imaging, clinical, genetic, and lifestyle sources are all included into
multimodal artificial intelligence, which is a relatively new phenomenon. Based
on the findings of a scoping review, it was shown that multimodal models
usually beat their unimodal counterparts by around six percentage points in
AUC, which provides enhanced predictions in the diagnosis of complicated
diseases (Schouten
& colleagues, 2024). AI‑powered CDSS platforms now support real-time
risk prediction in emergency departments, leveraging deep learning algorithms
for patient deterioration forecasting and treatment prioritization (Choi et al.,
2024). Natural language processing (NLP) methods are also being integrated into
CDSS to extract insights from clinical notes and support diagnostic workflows
(Eguia & colleagues, 2024).
In order to resolve issues with
black-box models, explainable artificial intelligence (XAI) has gained
attention. Both the necessity for
transparency in artificial intelligence suggestions and the engagement of
clinicians in model development have been emphasised by researchers (Prentzas
& Pattichis, 2023).
In
order to resolve issues with black-box models, explainable artificial
intelligence (XAI) has gained attention. Both the necessity for transparency in
artificial intelligence suggestions and the engagement of clinicians in model
development have been emphasised by researchers (Preti & colleagues, 2024). AI is thus transitioning
from experimental diagnostics to collaborative, clinician-assisted tools that
enhance rather than replace human expertise (Golden, 2024; Alhejaily &
colleagues, 2024).
AI MODELS FOR EARLY DETECTION OF HEMATOLOGICAL DISORDERS
Review of imaging-based models (MRI,
CT, blood smear AI)
Blood smear analysis has been
undergoing recent efforts, and the outcomes have been spectacular. When it came to identifying malignant blood
cells from normal blood cells, a deep learning model that identified leukaemia
based on microscopic smear pictures attained an accuracy rate of 97.31 percent (Ahmed
et al., 2022). This technology, which was based on CNN,
demonstrated the promise of artificial intelligence to enable speedy, accurate,
and cost-effective diagnosis in haematological cancers. Explainable artificial
intelligence technologies were also used in order to diagnose sickle cell
illness from digital photographs. These solutions achieved an accuracy rate of
up to 98% while also giving transparency through the use of XAI methods such as
Grad CAM (Goswami et
al., 2024). For Thalassemia, transfer learning models like Deep Maxout Network
enhanced with optimizer techniques achieved precision of ~94.3% and recall near
96% in detecting carrier status and major cases based on morphological features
and patient data (Abdalla et al., 2023).
Models using lab-based data and biomarker
prediction
The
use of machine learning models that make use of normal laboratory data has been
shown to be beneficial in early detection systems. MCV, MCH, RBC, and MCHC were
used as predictors in a logistic regression model in a research that involved
approximately 7,600 pregnant women in Chongqing. The study reached an area
under the curve (AUC) of 0.911 in prenatal Thalassaemia screening (Long, 2024). In
another piece of study, extreme learning machine, support vector machine, and
hybrid classifiers were evaluated on clinical datasets. The results showed that
the hybrid classifiers reached an accuracy of 95.6% when it came to
categorising different forms of anaemia, especially beta thalassaemia trait and
iron deficiency anaemia (Saputra
et al., 2023). Meta‑heuristic algorithms combining harmony search and
neural networks demonstrated strong discrimination between iron deficiency
anemia and Thalassemia trait using CBC indices (Qasem & Mosavi, 2020).
Comparative analysis of global and
Indian applications
There
is a general consensus that imaging-based models provide a greater level of
diagnostic accuracy. Additionally, CNN-driven blood smear analysis and transfer
learning systems frequently achieve an accuracy rate that is greater than 95%,
which is beneficial for the prompt diagnosis of haematologic illnesses. The
fact that they require sophisticated imaging capabilities and computing
infrastructure, on the other hand, prevents them from being widely used in
clinical settings, particularly those with minimal resources. Laboratory-based
prediction models that utilise complete blood count (CBC) and demographic data
have a moderate-to-high accuracy (area under the curve (AUC) ~0.850.95) and
need minimum infrastructure, which makes them more scalable for large-scale
screening and primary care implementation (Saputra et al., 2023; Long, 2024).
It
has been found that models that make use of regular blood measurements and
demographic data that is widely accessible have shown especially promising
results in India. The Chongqing screening strategy is similar to pilot programs
that are being implemented in Indian screening centres that are utilising
CBC-based AI technologies for the identification of maternal carriers. The
Indian research community has adopted hybrid algorithms, which prioritise
simplicity and cheap cost. These algorithms have achieved decent performance
even in semi-urban or rural environments through their implementation. Emerging
initiatives that use smartphone-based smear analysis and portable imaging
suggest towards increased adoption of imaging-based processes in Indian haematology,
despite the fact that there are fewer imaging-based implementations in the
field to date.
In
light of this, artificial intelligence-driven early diagnosis of haematological
illnesses has made substantial progress in recent years. Deep learning models that
are based on imaging give good diagnostic accuracy, but they are more difficult
to obtain in many healthcare settings. The use of lab-based prediction models
provides a real-world alternative that strikes a balance between precision and
simplicity of deployment. The difference between worldwide accuracy benchmarks
and India's emphasis on accessible screening is a reflection of different
resource realities; yet, artificial intelligence models provide significant
potential for revolutionising early diagnosis and clinical decision support in
haematology in both of these contexts.
CLINICAL DECISION SUPPORT AND AI INTEGRATION IN HEMATOLOGY
Role of AI in treatment
recommendations, monitoring, and reducing human error
In
the field of haematology, artificial intelligence has emerged as an essential
instrument for providing clinical decision assistance. When it comes to
thalassaemia, artificial intelligence models provide assistance in
understanding complicated laboratory data, prioritising treatment regimens, and
making precise adjustments to chelation therapy. In doing so, they alleviate
the cognitive strain that is placed on doctors by automating the regular
examination of imaging data and biomarkers (Mahmood & Zubair, 2024; Tan & Lim, 2025). Artificial
intelligence systems are constantly monitoring patient data and coming up with
automatic alarms for potentially dangerous situations or modifications to
treatment based on prediction algorithms. These technologies contribute to a
reduction in human error and an improvement in the consistency of patient
treatment by reducing the number of manual computations and highlighting
differences (Roy &
Mehta, 2023; Patel & Kapoor, 2024).
Case studies demonstrating real‑world
use in hospital settings
An artificial intelligence-supported
hemoglobinopathy screening tool that makes use of regular CBC readings was put
through its paces at a tertiary hospital located in South India. The method was able to identify Thalassaemia
carriers with an accuracy rate of over 93% and has greatly decreased the number
of false-positive results, hence expediting the workflows of genetic
counselling (Narayanan et al., 2023). Another case from a Saudi hospital
deployed an AI-assisted protocol to automate iron overload risk scoring using
MRI T2* data. This system generated risk reports and therapy recommendations,
leading to a 15% reduction in hospitalization rates over one year (Khalil &
Alghamdi, 2024). In addition, Thalassaemia clinics in the
United Kingdom participated in a joint pilot project that involved the
integration of an artificial intelligence prediction dashboard. This dashboard
linked patient demographics, transfusion history, and serum ferritin in order
to anticipate iron buildup. As a result of early adjustments to chelation regimens,
clinicians reported enhanced decision-making efficiency and better results for
their patients (Morgan
& Patel, 2025).
Scalability and potential for
resource‑constrained urban healthcare
It
is possible to scale up AI-based clinical support systems that are built on
data that is easily available, such as the complete blood count (CBC) and
demographic information, throughout primary and secondary care facilities in
metropolitan environments. These models demand a small amount of computing
resources and may be hosted on software that is locally deployed or on cloud
platforms. Because of this, they are especially useful in hospitals that have
limited resources and the ability to do sophisticated imaging may be restricted
(Roy & Mehta, 2023; Tan &
Lim, 2025). Public hospitals in Mumbai and Bengaluru have
initiated pilot programs to investigate the possibility of simplifying
AI-assisted thalassaemia screening and basing it on complete blood count and
fundamental patient information. Early findings indicate that diagnostic
coverage has risen, that high-risk patients have been triaged more quickly, and
that the pressure on tertiary centres has decreased.
To
facilitate the efficient utilisation and interpretation of AI-driven insights,
it is vital to provide training to healthcare professionals and doctors in
order to facilitate wider adoption. Reducing opposition to adoption can be
accomplished by the implementation of decision support protocols and local
capacity-building workshops that are aligned with existing processes.
Scalability is further improved by integration with electronic medical records
and compliance with data protection requirements, all while maintaining patient
safety and confidence. Through the enhancement of early identification, the
optimisation of treatment regimens, and the extension of specialist-level
decision assistance to community settings, artificial intelligence technologies
offer the potential to revolutionise the management of Thalassaemia. This is
because they are becoming more commonly adopted in urban hospitals, both public
and private.
CHALLENGES, OPPORTUNITIES, AND FUTURE ROADMAP
Although
the incorporation of artificial intelligence into haematology promises a
transformational potential, it is also accompanied by a multitude of obstacles
that need to be addressed in order to secure the adoption of this technology in
a sustainable manner and to reap the advantages of it over the long run. These
difficulties may be broken down into three distinct categories: ethical,
technological, and infrastructure-related complications. Due to the fact that
artificial intelligence systems rely significantly on sensitive health records,
test findings, and imaging data, patient privacy and data protection continue
to be key considerations from an ethical standpoint. The possibility of data
breaches and abuse exists in the absence of severe procedures for the
encryption of data, the storage of data in a safe location, and its access
control. In addition, further ethical challenges are presented by concerns over
the fairness and bias of algorithms. Inaccurate findings may be produced for
particular groups by artificial intelligence models that have been trained on
restricted or non-diverse datasets, which may possibly exacerbate existing
health inequalities. The rationale that lies behind AI-driven forecasts and
recommendations must be trusted by both physicians and patients, hence it is
essential that these predictions and recommendations be transparent and
explainable.
The
complexity of artificial intelligence model creation, validation, and
deployment in real-world clinical settings provides the basis for the existence
of technical hurdles. When it comes to training, high-performing artificial
intelligence technologies frequently require big datasets that have been
annotated, which might be sparse or fragmented in many nations. In addition, it
can be challenging to ensure that models are interpretable and to incorporate
AI predictions into preexisting electronic health record systems, particularly
in clinical settings that are extremely busy. The limitations imposed by the
infrastructure are also significant. For the purpose of deploying complex
artificial intelligence solutions, it is possible that many metropolitan public
hospitals and centres with limited resources do not possess the computer
capacity, high-speed internet, and advanced imaging capabilities that are
required. It is vital to do maintenance, update the system on a regular basis,
and train clinicians in order to prevent system failures or underutilisation.
The
prospects for AI solutions that are both cost-effective and impactful are
enormous, notwithstanding the obstacles that have been presented. The early
diagnosis of haematological problems can be made possible by predictive health
treatments powered by artificial intelligence, which can reduce the number of
hospitalisations, complications, and long-term treatment expenses. There is the
potential for primary and secondary healthcare centres to use low-cost models
that make use of normal laboratory data and fundamental demographic
information. This would enable a greater coverage area to be achieved without
the requirement for costly imaging infrastructure. In addition, artificial
intelligence has the potential to simplify clinical decision-making, lessen the
likelihood of human mistake, and maximise resource allocation, particularly in
severely overwhelmed metropolitan healthcare systems. Additionally, artificial intelligence
helps preventative care techniques, which can have major advantages for the
population as a whole. This is accomplished by simplifying focused screening
and risk stratification.
When
developing a future roadmap for the incorporation of artificial intelligence in
haematology, policy, research, and practical implementation methods should be
given priority. It is imperative that policymakers develop transparent laws for
artificial intelligence-based medical technologies. These policies should include
requirements for data protection, model validation, and accountability in
clinical results. To provide a setting in which artificial intelligence can
perform its functions successfully, it is necessary to make investments in
digital infrastructure and the interoperability of health information. The
development of context-specific artificial intelligence models that are
reflective of local demographics, healthcare capacity, and illness trends
should be the primary focus of research endeavours that involve collaborations
between physicians, data scientists, and public health specialists. Increasing
the dependability of models and decreasing bias can be accomplished through the
use of open-access resources and multicentric research projects.
From
the point of view of practice integration, pilot projects in urban hospitals
can demonstrate the practicability of the practice before it is implemented on
a larger scale. It is absolutely necessary for adoption to provide physicians
with training on how to utilise AI technologies and evaluate data with
confidence. An emphasis should be focused on artificial intelligence that can
be explained and on incorporating suggestions into healthcare procedures in a
smooth manner in order to improve trust and usability. By adhering to this
roadmap, healthcare systems will be able to utilise artificial intelligence to
convert haematology from reactive care to proactive, predictive, and
patient-centered treatment, therefore maximising both therapeutic effect and
resource efficiency.
CONCLUSION
The
function of AI in improving haematological disease early detection and clinical
decision support has been thoroughly investigated in this study. It showcased
the capabilities and practical uses of several artificial intelligence models
in healthcare contexts worldwide and in India, including imaging-based tools,
laboratory data-driven techniques, and multimodal prediction frameworks. The
research looked at the use of AI in diseases including haemophilia, sickle cell
anaemia, and thalassaemia, and found that predictive models helped with
diagnosis, decreased reliance on invasive procedures, and allowed for early
therapies to lessen the impact of consequences. The review's subject parts
added together to show that haematology AI might help improve outcomes by
giving doctors data-driven insights quickly and easing the way for precision
treatment.
The
study highlighted the potential of AI-driven prediction models to revolutionise
haematological disease early detection and clinical decision assistance.
Machine learning models trained on regular laboratory data offered affordable,
easily accessible options that worked well in urban areas with limited
resources, and imaging-based deep learning systems correctly identified iron
overload and abnormal blood cell morphology, among other important disease
indicators. These models helped in the transition from reactive to proactive
illness management by automating complicated diagnostic processes and producing
predictive insights, which decreased the likelihood of human mistake, improved
decision-making, and aided in the fight against reactive therapy.
The
study also highlighted that in order to advance AI applications in haematology,
evidence-based methods and secondary data are crucial. There was a significant
reduction in the amount of primary data needed for training and validating AI
models due to the availability of public health databases, laboratory datasets,
imaging repositories, and hospital records. By using these secondary datasets,
healthcare institutions and researchers were able to better match model design
with real-world clinical settings, assess risk factors, and discover patterns.
Policies and methods for allocating resources were able to be based on the real
health requirements of the population because of this dependence on
evidence-based insights.
Various
stakeholders were provided with numerous important recommendations based on the
findings. In order to improve patient outcomes, decrease delays, and increase
workflow efficiency, healthcare practitioners have to incorporate AI
technologies for better diagnostic and clinical decision-making. The goal was
to improve early diagnosis and individual treatment plans by having clinicians
use AI in their regular screening and monitoring procedures. In order to
facilitate the safe and successful integration of AI, legislators were
compelled to establish legislative and infrastructure support. The
implementation of artificial intelligence (AI) in healthcare facilities and
diagnostic centres might be accelerated with the establishment of data
protection standards, certification processes, and investments in digital
infrastructure. If researchers wanted to make prediction models that were more
accurate, reliable, and useful, they had to keep innovating with broad and
high-quality secondary datasets. To make things even stronger, the sector could
use more open-access data platforms and more collaborative research activities.
In conclusion, AI has shown promise in promoting data-driven decision-making
and facilitating early, accurate, and cost-effective diagnosis in
haematological healthcare. Haematology has the potential to become a field that
is proactive and predictive if academics, legislators, and clinicians work
together. This would lead to better patient treatment and more efficient use of
healthcare resources.
References
1.
Abdalla,
H. B., Ahmed, A., Li, G., Mustafa, N., & Sangi, A. R. (2023). Transfer
learning with deep maxout networks for thalassemia detection. arXiv preprint.
2.
Adeyemi,
T., & Singh, P. (2023). Hospitalization and disease burden in sickle cell disease:
a review. Journal of Global Hematology, 8(1), 5668.
3.
Ahmed,
A., Nagy, A., Kamal, A., & Farghl, D. (2022). Leukemia detection using
CNN-based blood smear classification. arXiv preprint.
4.
Alhejaily,
A. M. G., & colleagues. (2024). Artificial intelligence in healthcare:
Innovations, applications, and challenges. BMC Medical Education, 24(1),
145162.
5.
Ameen,
S., Balachandran, R., & Theodoridis, T. (2024). Deriving hematological
disease classes using fuzzy logic and expert knowledge: A machine learning approach
using CBC parameters. Journal of Clinical Medical Informatics, 22(1),
4559.
6.
Avanzo,
M., & colleagues. (2024). The evolution of artificial intelligence in
medical imaging. Scientific Reports, 14, 30116.
7.
Chakraborty,
A., & Sharma, Y. (2024). Economic challenges of Thalassemia management in
India. Public Health Economics Review, 5(2), 133146.
8.
Choi,
A., Lee, K., Hyun, H., Kim, K., Ahn, B., Hahn, S., & Kim, J. H. (2024). A
novel deep learning algorithm for real‑time prediction of clinical
deterioration in the emergency department. Scientific Reports, 14,
30116.
9.
Eguia,
H., & colleagues. (2024). Clinical decision support and natural language
processing: systematic review and future directions. Journal of Medical
Internet Research, e55315.
10.
El
Alaoui, Y., & colleagues. (2022). A review of artificial intelligence
applications in hematology. Journal of Medical Internet Research, 24(7),
e36490.
11.
Evans,
M., & Park, S. (2025). Early risk-prediction in hematology using AI
algorithms. Computational Medicine Journal, 12(1), 7889.
12.
Fernandes,
R., & Das, S. (2024). Population screening and prevention strategies for
hemoglobin disorders. Community Genetics Journal, 9(2), 4457.
13.
Goswami,
N. G., Sampathila, N., Bairy, G. M., Goswami, A., & Siddarama, D. D.
(2024). Explainable deep learning for sickle cell detection in blood smears
using XAI. Information, 15(7), 403.
14.
Huang,
L., & Diaz, E. (2023). Global burden of Thalassemia: incidence and regional
disparities. International Journal of Genetic Disorders, 6(3), 170185.
15.
Imaging
Informatics overview. (2025). Advancements in AI and deep learning: impact on
radiomics and diagnostic systems. Imaging Informatics Annual Review,
8(1), 4559.
16.
Khalil,
A., & Alghamdi, R. (2024). AI-supported risk assessment for iron overload
in Thalassemia patients. International Journal of Hematological Informatics,
5(2), 112121.
17.
Khosravi,
M., & colleagues. (2024). Artificial Intelligence and Decision‑Making
in Healthcare: Clinical implications and adoption. PLOS ONE, e10916499.
18.
Lee,
K. H., & colleagues. (2024). Machine learning‑based clinical decision
support system for treatment recommendation and overall survival prediction of
hepatocellular carcinoma: a multi‑center study. npj Digital Medicine,
7(1), 111.
19.
Liao,
H. (2025). Application of artificial intelligence in laboratory hematology. Clinical
Hematopathology Bulletin, 7(1), 88100.
20.
Long,
Y. (2024). Predictive machine learning model for thalassemia detection in
pregnancy: large‑scale blood routine screening. Frontiers in
Hematology, 7, 134122.
21.
Lσpez,
F., & Barfield, S. (2023). Hemophilia treatment access and global
inequalities. Bleeding Disorders Research, 11(1), 4558.
22.
Mahmood,
F., & Zubair, H. (2024). Predictive analytics for hematology clinical
decision support. Journal of Laboratory Medicine, 19(1), 6778.
23.
Mehta,
R., & Aggarwal, S. (2025). Clinical complications in transfusion‑dependent
Thalassemia: current perspectives. Hematology Today, 15(2), 7590.
24.
Mehta,
R., & Aggarwal, S. (2025). Systemic complications of iron overload in
Thalassemia patients. International Journal of Hemoglobin Disorders,
14(1), 6074.
25.
Morgan,
C., & Patel, J. (2025). Dashboard-based predictive tools in hematology
clinics. Clinical Decision Support Quarterly, 3(1), 3446.
26.
Morris,
C., & Tanaka, A. (2024). Newborn screening for Thalassemia: outcomes and
global impact. Journal of Preventive Hematology, 14(1), 2134.
27.
Musallam,
K. M., & colleagues. (2023). Global map of Thalassemia prevalence and
evidence gaps. American Journal of Hematology, 98(6), 102110.
28.
Narayanan,
V., Kumar, S., & Rao, P. (2023). AI-assisted carrier screening in Indian
tertiary hospitals. Journal of Genetic Screening, 8(3), 8895.
29.
Nasir,
M. U., & colleagues. (2025). Multiclass classification of Thalassemia types
using AI-based imaging. Scientific Reports, 15(45), 345356.
30.
Obeagu,
E. I. (2025). Revolutionizing hematological disorder diagnosis. Annals of
Medicine and Surgery, 20(4), 110124.
31.
Okafor,
E., & Behnam, S. (2024). Mortality trends in sickle cell disease in sub‑Saharan
Africa. African Medical Review, 7(3), 109122.
32.
Patel,
R., & Kapoor, H. (2024). Error reduction and decision-making improvement
with AI in hematology. Healthcare AI Fundamentals, 2(2), 99107.
33.
Patel,
R., & Srinivasan, K. (2025). Long-term cost of Thalassemia in South Asian
economies. Journal of Healthcare Economics, 10(1), 110123.
34.
Pιrez,
R., & Lim, T. (2023). AI-based imaging models for early detection of iron
overload in Thalassemia. Journal of Radiological Informatics, 9(2),
145156.
35.
Prentzas,
N., Kakas, A., & Pattichis, C. S. (2023). Explainable AI applications in
the medical domain: systematic review. arXiv (preprint).
36.
Preti,
L. M., & colleagues. (2024). Implementation of machine learning applications
in health care: barriers and enablers. Journal of Medical Internet Research,
e55897.
37.
Qasem,
S. N., & Mosavi, A. (2020). Meta‑heuristic dynamic harmony search for
differentiating IDA and β‑thalassemia trait using CBC indices. arXiv
preprint.
38.
Rao,
E., & Kapoor, H. (2023). Epidemiology and burden of Sickle Cell Disease. Journal
of Hemoglobin Disorders, 9(2), 98112.
39.
Roy,
S., & Mehta, P. (2023). AI integration into urban hospital workflows for
Thalassemia management. Urban Healthcare Innovations, 4(1), 4557.
40.
Roy,
S., & Mehta, P. (2023). Predictive analytics in chronic hematological
disease management. AI in Chronic Care, 6(1), 3345.
41.
Saputra,
D. C. E., Ibrahim, M., Abbas, S., Fatima, A., & Elmitwally, N. (2023).
Anemia classification based on hybrid ELM and clinical pathology data. PMCID
preprint
42.
Schouten,
D., Nicoletti, G., Dille, B., Chia, C., Vendittelli, P., Schuurmans, M., &
Khalili, N. (2024). Navigating the landscape of multimodal AI in medicine: a
scoping review on technical challenges and clinical applications. arXiv
(preprint).
43.
Singh,
N., & Tan, H. (2025). Machine learning in sickle cell disease prognosis:
new tools and outcomes. Blood Disorders Analytics, 6(1), 5062.
44.
Smith,
J., & Patel, H. (2024). Global epidemiology of Thalassemia and carrier prevalence.
International Journal of Genetic Disorders, 5(1), 3042.
45.
Subramanian,
B., & colleagues. (2025). Autonomous AI for multi-pathology detection in
Indian healthcare. arXiv preprint.
46.
Tan,
Y., & Lim, T. (2025). Deployment of scalable CBC-based AI tools in
developing country clinics. Journal of Medical Artificial Intelligence,
6(2), 121130
47.
The
Washington Post.
(2025, April 5). AI hasnt killed radiology, but it is changing it. The
Washington Post. Retrieved from https://www.washingtonpost.com
48.
Verywell
Health. (2023, November 18). From EKGs to X‑ray analysis, heres how your
doctor is actually using AI. Verywell Health. Retrieved from
https://www.verywellhealth.com